BiotechTube
Home/Biohaven/John W. Childs, Ph.D.
JW

John W. Childs, Ph.D.

Chief Business Officer

Biohaven

Therapeutic Areas

NeuroscienceImmunologyOncology

Biohaven Pipeline

DrugIndicationPhase
TroriluzoleSpinocerebellar Ataxia (SCA)Phase 3
Taldefgrobep Alfa (BHV-8000)Obesity (with GLP-1)Phase 2
Taldefgrobep AlfaSpinal Muscular Atrophy (SMA)Phase 3
BHV-7000Focal EpilepsyPhase 2/3
BHV-1300Immunology / OncologyPhase 1/2
BHV-1100Immunology / OncologyPhase 1
BHV-2100UndisclosedDiscovery/Preclinical

Leadership Team at Biohaven

VC
Vlad Coric, M.D.
Chairman & Chief Executive Officer
BL
Bruce Leuchter, M.D.
Chief Financial Officer
IA
Irina Antonijevic, M.D., Ph.D.
Chief Medical Officer
RB
Robert Berman, M.D.
Chief Translational Officer
View full Biohaven profile